These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 17541722)
1. Can intravenous immunoglobulin and simvastatin solve the problem of sensitization in renal transplant candidates? Mahmoud KM; Sobh MA; El-Shenawy F; Isamil AM; El-Magd MA; Hassan NA; El-Agroudy AE; Sheashaa HA; Opelz G; Ghoneim MA Int Urol Nephrol; 2007; 39(3):979-81. PubMed ID: 17541722 [TBL] [Abstract][Full Text] [Related]
2. Management of sensitized patients awaiting renal transplantation: does sequential therapy of intravenous immunoglobulin and simvastatin offer a solution? Mahmoud KM; Sobh MA; El Shenawy F; Isamil AM; El-Magd MA; Hassan NA; El-Agroudy AE; Sheashaa HA; Opelz G; Ghoneim MA Eur J Pharmacol; 2007 Apr; 561(1-3):202-5. PubMed ID: 17296177 [TBL] [Abstract][Full Text] [Related]
3. Effect of high-dose intravenous immunoglobulin on suppression of alloantibodies against hla in highly sensitized transplant candidates. Mahmoud K; Sobh M; El-Shenawy F; Mostafa A; Abo El Magd M; Hassan N; El-Agroudy A; Sheashaa H; Opelz G; Ghoneim M Transplant Proc; 2004; 36(6):1850-2. PubMed ID: 15350496 [TBL] [Abstract][Full Text] [Related]
4. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614 [TBL] [Abstract][Full Text] [Related]
5. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854 [TBL] [Abstract][Full Text] [Related]
6. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants. Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404 [TBL] [Abstract][Full Text] [Related]
7. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Kozlowski T; Andreoni K Ann Transplant; 2011; 16(2):19-25. PubMed ID: 21716181 [TBL] [Abstract][Full Text] [Related]
11. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report. Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279 [TBL] [Abstract][Full Text] [Related]
12. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100 [TBL] [Abstract][Full Text] [Related]
14. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients. Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R Clin Transpl; 2014; ():215-21. PubMed ID: 26281148 [TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients. Valentini RP; Nehlsen-Cannarella SL; Gruber SA; Mattoo TK; West MS; Lang C; Imam AA Pediatr Transplant; 2007 Feb; 11(1):77-81. PubMed ID: 17239127 [TBL] [Abstract][Full Text] [Related]
16. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Vo AA; Petrozzino J; Yeung K; Sinha A; Kahwaji J; Peng A; Villicana R; Mackowiak J; Jordan SC Transplantation; 2013 Mar; 95(6):852-8. PubMed ID: 23511212 [TBL] [Abstract][Full Text] [Related]
17. Desensitized renal transplant recipients show reduced cellular responses to in vitro challenge. Kimball P; King A Transplant Proc; 2006 Dec; 38(10):3416-7. PubMed ID: 17175290 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic Effect of Plasmapheresis and Intravenous Immunoglobulin in Recipients of Kidney Transplant With High Panel-reactive Antibody Levels: A Single-center Experience. Sendogan DO; Saritas H; Kumru G; Erdogmus S; Tuzuner A; Keven K; Sengul S Transplant Proc; 2019 Sep; 51(7):2254-2256. PubMed ID: 31474291 [TBL] [Abstract][Full Text] [Related]
19. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Magee CC; Felgueiras J; Tinckam K; Malek S; Mah H; Tullius S Transplantation; 2008 Jul; 86(1):96-103. PubMed ID: 18622284 [TBL] [Abstract][Full Text] [Related]
20. Use of high-dose human immune globulin in highly sensitized patients on the kidney transplant waiting list: one center's experience. Gozdowska J; Urbanowicz A; Perkowska-Ptasinska A; Michalska K; Chmura A; Szmidt J; Durlik M Transplant Proc; 2009 Oct; 41(8):2997-3001. PubMed ID: 19857660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]